COMPARE · Reviewed August 7, 2026
DOCS vs HALO
Verdict: Side-by-side breakdown using the Bull Rankings model. DOCS scored 89.5, HALO scored 82.7 — DOCS leads.
Compare another set
DOCS
Doximity, Inc.
89.5
$20.66 · $3.7B
fundamentals as of
Score gap
6.8
DOCS leads
HALO
Halozyme Therapeutics, Inc.
82.7
$85.76 · $10.2B
fundamentals as of
The model, pillar by pillar (0–100 each)
DOCS
stronger →← stronger
HALO
88
Qualityreturns · margins · balance sheet
85
90
Growthrevenue & earnings expansion
100
90
Valuevaluation vs sector peers
67
DOCS is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
DOCS
HALO
$306mC
FCF
$806mC+
+11.2%B
Rev
+41.2%A
0.01A
D/E
9.91D
21.1xB+
P/E
30.1xB
0.59A-
PEG
0.80A-
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
DOCS
HALO
20% below
Price vs fair valuelower is cheaper
51% below
~2%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-4%/yr
+12%
1-yr DCF upside
+59%
+25%
5-yr DCF upside
+105%
+44%
10-yr DCF upside
+200%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DOCS
Why this score
- Durable high returns
HALO
Why this score
- Buying back stock
- Durable high returns
The companies
DOCSDoximity, Inc.
Why now
Health Information Services · market cap $3.7b. Down 73% from 52-week high of $76.51 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. PEG 0.59 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Buy with a mean 1-yr target of $24.61 (implying +19% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 183% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 73% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $10.2b. Trading near 52-week high of $86.00 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. PEG 0.80 — paying under fair value for the growth rate. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $86.89 (implying +1% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 9.91 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.